Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility Study of Caffeine on CVD Biomarkers
NCT06359197Phase 1Not yet recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of caffeine in cardiovascular disease (CVD) (4 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Participant rate, Participant Adherence and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
caffeine
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT06359197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359197.